Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Cruz-Nova P"'
Autor:
Diana Trujillo-Benítez, Myrna Luna-Gutiérrez, José G. Aguirre-De Paz, Pedro Cruz-Nova, Gerardo Bravo-Villegas, Joel E. Vargas-Ahumada, Paola Vallejo-Armenta, Enrique Morales-Avila, Nallely Jiménez-Mancilla, Rigoberto Oros-Pantoja, Clara Santos-Cuevas, Erika Azorín-Vega, Blanca Ocampo-García, Guillermina Ferro-Flores
Publikováno v:
Pharmaceutics, Vol 16, Iss 4, p 532 (2024)
Recently, we reported a new fibroblast activation protein (FAP) inhibitor radiopharmaceutical based on the 99mTc-((R)-1-((6-hydrazinylnicotinoyl)-D-alanyl) pyrrolidin-2-yl) boronic acid (99mTc-HYNIC-D-Alanine-BoroPro)(99mTc-HYNIC-iFAP) structure for
Externí odkaz:
https://doaj.org/article/0fdb43edc9aa47f6b9827a930acef9fb
Autor:
Pedro Cruz-Nova, Brenda Gibbens-Bandala, Alejandra Ancira-Cortez, Gerardo Ramírez-Nava, Clara Santos-Cuevas, Myrna Luna-Gutiérrez, Blanca Ocampo-García
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
IntroductionMore than 1.9 million new cases of colorectal cancer and 935,000 deaths were estimated to have occurred worldwide in 2020. Therapies for metastatic colorectal cancer include cytotoxic chemotherapy and targeted therapies in multiple lines
Externí odkaz:
https://doaj.org/article/40823603a990461e9856085094bdbe1f
Autor:
Guillermina Ferro-Flores, Blanca Ocampo-García, Pedro Cruz-Nova, Myrna Luna-Gutiérrez, Gerardo Bravo-Villegas, Erika Azorín-Vega, Nallely Jiménez-Mancilla, Emiliano Michel-Sánchez, Osvaldo García-Pérez, Nancy Lara-Almazán, Clara Santos-Cuevas
Publikováno v:
Pharmaceutics, Vol 15, Iss 12, p 2662 (2023)
Recent cancer therapies have focused on reducing immune suppression in the tumor microenvironment to prevent cancer progression and metastasis. PD-1 is a checkpoint protein that stops the immune response and is expressed on immune T cells. Cancer cel
Externí odkaz:
https://doaj.org/article/2e6c59ca67464c6e85d204f50551568c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Tania Hernández-Jiménez, Pedro Cruz-Nova, Alejandra Ancira-Cortez, Brenda Gibbens-Bandala, Nancy Lara-Almazán, Blanca Ocampo-García, Clara Santos-Cuevas, Enrique Morales-Avila, Guillermina Ferro-Flores
Publikováno v:
Nanomaterials, Vol 12, Iss 23, p 4181 (2022)
The fibroblast activation protein (FAP) is heavily expressed in fibroblasts associated with the tumor microenvironment, while the prostate-specific membrane antigen (PSMA) is expressed in the neovasculature of malignant angiogenic processes. Previous
Externí odkaz:
https://doaj.org/article/a45ed9b713f1416fb1cfeaa2c76bf181
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Pedro Cruz-Nova, Blanca Ocampo-García, Dayan Andrea Carrión-Estrada, Paola Briseño-Diaz, Guillermina Ferro-Flores, Nallely Jiménez-Mancilla, José Correa-Basurto, Martiniano Bello, Libia Vega-Loyo, María del Rocío Thompson-Bonilla, Rosaura Hernández-Rivas, Miguel Vargas
Publikováno v:
Molecules, Vol 27, Iss 17, p 5446 (2022)
In 40–50% of colorectal cancer (CRC) cases, K-Ras gene mutations occur, which induce the expression of the K-Ras4B oncogenic isoform. K-Ras4B is transported by phosphodiesterase-6δ (PDE6δ) to the plasma membrane, where the K-Ras4B–PDE6δ comple
Externí odkaz:
https://doaj.org/article/959c68d2b2ad4ca5bef06490fac95d9a
Autor:
Pedro Cruz-Nova, Alejandra Ancira-Cortez, Guillermina Ferro-Flores, Blanca Ocampo-García, Brenda Gibbens-Bandala
Publikováno v:
Pharmaceutics, Vol 14, Iss 5, p 1095 (2022)
Nanoparticles are excellent platforms for several biomedical applications, including cancer treatment. They can incorporate different molecules to produce combinations of chemotherapeutic agents, radionuclides, and targeting molecules to improve the
Externí odkaz:
https://doaj.org/article/ca9e9d9564714653857d395e9629df59
Autor:
Pedro Cruz-Nova, Michael Schnoor, José Correa-Basurto, Martiniano Bello, Paola Briseño-Diaz, Arturo Rojo-Domínguez, Carlos M. Ortiz-Mendoza, Jorge Guerrero-Aguirre, Francisco J. García-Vázquez, Rosaura Hernández-Rivas, María del Rocío Thompson-Bonilla, Miguel Vargas
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-13 (2018)
Abstract Background Colorectal cancer is the third most common cancer worldwide; and in 40% of all cases, KRAS4b-activating mutations occur. KRAS4b is transported by phosphodiesterase-6δ (PDEδ) to the plasma membrane, where it gets activated. PDEδ
Externí odkaz:
https://doaj.org/article/d7e15b2f30de437f86fb762cc8e99987